Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

This study has been completed.
Information provided by (Responsible Party):
Clavis Pharma Identifier:
First received: July 9, 2007
Last updated: August 28, 2013
Last verified: August 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2008
  Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 28, 2013